Rare but serious side effects include:
- Guillain-Barre syndrome
- Other neurological complications
Rare cases of anaphylactic shock have been reported after receiving some preparations containing the tetanus toxoid.
GENERIC AVAILABLE: Yes
PREPARATIONS: Vial: 0.5 ml unit dose & 5 ml vial
STORAGE: Tetanus toxoid vaccines should be refrigerated between 2.2 C and 7.7 C (36 F and 46 F). Do not freeze.
DOSING: The recommended dose is 0.5 ml injected intramuscularly. Repeat at 4 to 8 weeks after the first dose and at 6 to 12 months after the second dose.
Some medications may decrease the therapeutic benefits of the tetanus toxoid vaccine. Example of such medications include:
- fingolimod (Gilenya)
- belimumab (Benlysta)
- anakinra (Kineret)
- adalimumab (Humira)
- infliximab (Remicade)
- Antineoplastic agents (anti-cancer medications)
PREGNANCY: Tetanus toxoid is classified as FDA pregnancy risk category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Adequate and well-controlled studies of the tetanus toxoid vaccine in pregnant women are lacking.
NURSING MOTHERS: It is not known if tetanus toxoid is excreted in breast milk.
REFERENCE: FDA Prescribing Information.
Quick GuideTravel Health: Vaccines & Preventing Diseases Abroad
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.